PDF-8 September 2014EMA//2011Rev 1*Guideline on good pharmacovigilance pra
Author : giovanna-bartolotta | Published Date : 2017-02-22
Draft Revision 1 agreed by ERMS FG29 May 2013 Draft Revision 1 adopted by Executive Director6 June 2013 Released for public consultation7 June 2013 nd of consultation
Presentation Embed Code
Download Presentation
Download Presentation The PPT/PDF document "8 September 2014EMA//2011Rev 1*Guideline..." is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
8 September 2014EMA//2011Rev 1*Guideline on good pharmacovigilance pra: Transcript
Draft Revision 1 agreed by ERMS FG29 May 2013 Draft Revision 1 adopted by Executive Director6 June 2013 Released for public consultation7 June 2013 nd of consultation deadline for comments5 August 2. Title of the event – (Arial 28pt bold). Subtitle for event – (Arial 28pt). Standard formula appropriateness for life and general insurers. Head of Department, General Insurance Actuaries. James Orr. Manager, Retail General Insurance Team . 1. The . PRA Approach to . Supervision for Smaller Insurers. Topics:. 1.1 The Regulatory Framework. 1.2 Firm Categorisation. 1.3 The Supervisory Approach. 1.4 Regulatory Co-ordination. Page 1 of 6 General A PRA is the body, statutory or otherwise, that has the control and general supervision of racing within a State or Territory, and means in the State of New South Wales, Racing NSW New challenges for WHO. Dr Shanthi Pal. . Group Lead, Medicines Safety . . Director/EMP . K. De . Joncheere. Coordinator PAU. G. Forte. Head/RHT. L.Rago. Coordinator/PHI. M Zafar. Coordinator /PQT. An Educational Program to Improve the Level of Teaching Risk-Informed, Performance-based Fire Protection Engineering Assessment Methods. 1. 1.6 Fire Modeling in Support of . Fire PRA. Fire PRA primarily applies fire modeling in the fire scenario development and analysis process. . New challenges for WHO. Dr Shanthi Pal. . Group Lead, Medicines Safety . . Director/EMP . K. De . Joncheere. Coordinator PAU. G. Forte. Head/RHT. L.Rago. Coordinator/PHI. M Zafar. Coordinator /PQT. JAMASOFT2017. 1. Social. Pharmacy. Pharmacoepidemiology. Pharmacovigilance. JAMASOFT2017. 2. P. armacovigilance. system collects data . throughout the . lifecycle . of each . medicinal. . product. Chris Donald. Agenda. The PRA’s approach. Supervisory Committees. Key themes in Northern Ireland credit unions. Upcoming work. Questions. The PRA Approach. Not . for the PRA to ensure no credit union fails. , MD. Pfizer, India. DISCLAIMER. Overview. Introduction & Terminology. Why Pharmacovigilance?. Pharmacovigilance Practices. : International & Indian. PVPI. Drug Safety Issues in Clinical Trials . Monitoring the safety of medicines. Pharmacovigilance is the science and practices related to the detection, assessment, understanding, and prevention of adverse effects or any other medicine-related problem. Shanthi Pal. Leader, Medicines Safety. Safety . and Vigilance,. WHO, Geneva. What is pharmacovigilance. The science and activities relating to the detection, assessment, understanding and prevention of . 1466 Nikhil GuptaKavita BahmaniAjit Jangra IntroductionPharmacovigilance and drug safety remains As per the World Health Organization (WHO), Pharmacovigilance may be dened ClinicalPractice ISSN No medicine is without . risk and the. . benefits of . a medicine must always be weighed up against its risks. . The . balance of benefits and risks should be effectively considered and must not be left to chance. A public hearing is a forum to which the public is invited to express its views and concerns on a pre-defined set of questions on issues related to the safety of a particular medicine while also considering its therapeutic effects..
Download Document
Here is the link to download the presentation.
"8 September 2014EMA//2011Rev 1*Guideline on good pharmacovigilance pra"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.
Related Documents